Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 490 | 79 | 402 |
| Samples | 208 | 39 | 166 |
| Peptides | 150 | 26 | 127 |
Function
CEACAM3 · CEA cell adhesion molecule 3
This gene encodes a member of the family of carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), which are used by several bacterial pathogens to bind and invade host cells. The encoded transmembrane protein directs phagocytosis of several bacterial species that is dependent on the small GTPase Rac. It is thought to serve an important role in controlling human-specific pathogens by the innate immune system. Alternatively spliced transcript variants have been described. [provided by RefSeq, Mar 2013].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 134 amino-acid changes on canonical ENST00000357396 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CEACAM3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CEACAM3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 12/612 2% |
| Other Solid Cancers | 2/94 2% | 32/1515 2% |
| Melanoma | 4/210 2% | 30/1899 2% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Colorectal Carcinoma | 4/143 3% | 20/3239 1% |
| Cervical Carcinoma | 2/35 6% | 1/422 0% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 5/1390 0% |
| Kidney Carcinoma | 2/85 2% | 9/1862 0% |
| Hepatocellular Carcinoma | 2/46 4% | 9/2210 0% |
| Gastric Carcinoma | 0/74 0% | 8/1809 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Esophageal Carcinoma | 1/23 4% | 2/769 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Prostate Carcinoma | 1/13 8% | 2/2105 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 1/2550 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 2/2534 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
Mutation Distribution
Where CEACAM3 is mutated · all tissues, split by cell line vs tissue
How many mutations in CEACAM3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 490 mutations in CEACAM3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|